Skip to main content
Figure 1 | Health and Quality of Life Outcomes

Figure 1

From: Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study

Figure 1

Mean PCS Scores Across 16 Weeks for REVEAL Trial Groups Versus General US Population. General US population is the entire MEPS population (N = 23,517). SF-12 values from entire MEPS population controlled for age, sex, and race. Sample size for adalimumab group at baseline and Week 16: n = 805 and n = 755. Sample size for placebo group at baseline and Week 16: n = 396 and n = 354. Analysis of covariance with Bonferroni adjustment for multiple comparisons. *p < 0.0001

Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us